Skip to main content
. 2021 Apr 27;12:649010. doi: 10.3389/fmicb.2021.649010

FIGURE 2.

FIGURE 2

Feasibility assessment of the CRISPR-Cas12b-based C. jejuni detection system. (A) The cis-cleavage activity of Cas12b. Lane M, DL1000 Marker. Lane 1: cleavage by Cas12b of the PCR product. In this system, the PCR product (substrate of Cas12b), sgRNA, Cas12b, and other reagents were added. Lane 2: negative control. Cas12b was not added in the system. (B) The trans-cleavage activity of Cas12b. Upper panel, Tube 1: all required components were added; Tube 2: the 5′−6FAM-N12-3′-BHQ1 probe was not included; Tube 3: only Cas12b was added; Tube 4: only template DNA was added; Tube 5: only the 5′−6FAM-N12-3′-BHQ1 probe was added. Lower panel: fluorescence intensity corresponding to each tube in panel (B) upper panel. Paired two-tailed t test, p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. ND, Not detected. NC, Negative control.